Ga-68-DOTATATE Uptake in Pancreatic Metastasis of Renal Cell Carcinoma Mimicking Pancreatic Neuroendocrine Tumor

Creative Commons License

Soydal Ç., Nak D., Araz M., Demirkazık A., Küçük N. Ö.

CLINICAL NUCLEAR MEDICINE, vol.44, no.10, pp.795-796, 2019 (SCI-Expanded) identifier

  • Publication Type: Article / Editorial Material
  • Volume: 44 Issue: 10
  • Publication Date: 2019
  • Doi Number: 10.1097/rlu.0000000000002718
  • Journal Name: CLINICAL NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.795-796
  • Keywords: Ga-68-DOTATATE, PET, renal cell carcinoma, PET/CT, MANAGEMENT
  • Ankara University Affiliated: Yes

Abstract

A 61-year-old man, with a history of prior clear cell renal cell carcinoma in remission, was referred to Ga-68-DOTATATE PET/CT for the further evaluation of pancreatic tail mass. Ga-68-DOTATATE PET/CT showed pathologically intense uptake on the pancreatic mass; subsequent biopsy of the pancreatic mass confirmed the diagnosis of clear cell renal cell carcinoma metastasis. Ga-68-DOTATATE uptake is not specific for neuroendocrine tumors. In the presence of prior malignancy, it should be kept in mind that malignancies apart from neuroendocrine tumors express somatostatin receptors, and they can show Ga-68-DOTATATE uptake.